Ophthalmology – Radiation Optic Neuropathy

Basics

Description

Radiation-induced optic neuropathy (RION) is a delayed, usually severe optic neuropathy caused by previous radiation exposure to the:

• Optic nerve
• Optic chiasm
• Occasionally optic tract

It most often occurs after radiotherapy for tumors involving or adjacent to the anterior visual pathway, including:

• Orbit
• Paranasal sinuses
• Skull base
• Sella/parasellar region
• Nasopharynx
• Intracranial tumors near the optic apparatus

The typical presentation is:

Sudden or rapidly progressive, painless visual loss months to years after radiotherapy

RION is usually irreversible and must be distinguished urgently from:

Recurrent or progressive tumor, which may require specific treatment.

Clinical Importance

New visual loss in a patient with previous radiation near the optic pathways should prompt urgent evaluation for:

• Radiation-induced optic neuropathy
• Recurrent/compressive tumor
• Tumor infiltration
• Optic neuritis
• Ischemic optic neuropathy
• Meningeal carcinomatosis
• Radiation retinopathy

The diagnosis should not be assumed solely because of a history of radiotherapy.

Epidemiology

RION is uncommon with modern radiation planning but remains a serious delayed complication.

Risk is strongly related to:

• Total radiation dose
• Dose per fraction
• Volume of optic nerve/chiasm irradiated
• Radiation technique
• Patient-specific vascular susceptibility

Latency

RION most often develops:

Several months to several years after treatment

A common interval is approximately:

1–3 years

but cases may occur earlier or substantially later.

A very long latency does not completely exclude RION.

Laterality

Disease may be:

• Unilateral
• Sequentially bilateral
• Bilateral simultaneously

If the chiasm is involved, both eyes may be affected through:

• Chiasmal field loss
• Bilateral optic nerve dysfunction

Risk Factors

Important risk factors include:

• High radiation dose to the optic apparatus
• Large dose per fraction
• Stereotactic/high-dose focal treatment near optic nerve or chiasm
• Re-irradiation
• Concurrent or prior chemotherapy
• Diabetes mellitus
• Hypertension
• Preexisting optic nerve compression
• Other vascular risk factors

Radiation Dose and Risk

For conventional fractionated radiotherapy, the risk of RION rises substantially when the optic nerve or chiasm receives doses above approximately:

50–55 Gy

particularly when:

• Fraction size exceeds approximately 1.8–2 Gy
• Large segments of the optic pathway are irradiated

Modern radiation planning generally attempts to keep maximum optic nerve/chiasm dose below established organ-at-risk constraints whenever tumor control allows.

Stereotactic Radiosurgery

The optic nerve and chiasm are particularly sensitive to:

High single-fraction doses

Therefore single-fraction radiosurgery immediately adjacent to a functioning optic apparatus requires strict dose limitation.

Fractionated stereotactic radiotherapy may be preferred when a lesion lies very close to:

• Optic nerve
• Chiasm

because fractionation reduces the risk of delayed radiation injury.

Pathophysiology

RION is believed to result from a combination of:

• Radiation-induced vascular injury
• Endothelial damage
• Capillary occlusion
• Ischemia
• Demyelination
• Direct glial and axonal injury

Vascular Injury

Radiation damages small blood vessels through:

• Endothelial proliferation
• Fibrinoid necrosis
• Obliterative endarteritis
• Capillary closure

The result is:

Chronic ischemia of the optic nerve

Parenchymal Injury

Radiation may also directly damage:

• Oligodendrocytes
• Astrocytes
• Myelin
• Axons

leading to:

• Demyelination
• Necrosis
• Axonal loss

The final pathology is therefore both:

Vascular and neural.

Clinical Presentation

The classic symptom is:

Painless visual loss

which may be:

• Sudden
• Subacute
• Rapidly progressive over days to weeks

Vision loss is often severe.

Visual Acuity

Visual acuity may decline to:

• 20/200 or worse
• Counting fingers
• Hand motions
• No light perception in severe cases

Visual prognosis is generally poor once substantial injury is established.

Color Vision

Patients commonly have:

Marked dyschromatopsia

consistent with optic nerve dysfunction.

Pupillary Findings

If involvement is unilateral or asymmetric:

Relative afferent pupillary defect (RAPD)

is expected.

Bilateral symmetric disease may produce no obvious RAPD.

Visual Fields

Field defects depend on the location of injury.

Optic Nerve

Possible defects include:

• Central scotoma
• Cecocentral scotoma
• Arcuate defect
• Altitudinal defect
• Diffuse depression

Optic Chiasm

May produce:

• Bitemporal hemianopic defects

Optic Tract

May produce:

• Contralateral homonymous visual field loss

Optic Disc Appearance

At onset, the optic disc may appear:

• Normal
• Mildly swollen
• Pale if there was prior compressive damage

Anterior optic nerve involvement may produce:

Disc edema

but many cases are retrobulbar and initially have a normal-appearing disc.

Optic Atrophy

Over subsequent weeks:

Optic disc pallor develops

because of irreversible axonal loss.

This may be accompanied by:

• RNFL thinning
• Ganglion cell loss

Radiation Retinopathy

RION may coexist with:

Radiation retinopathy

especially when the globe was within the radiation field.

Look for:

• Microaneurysms
• Cotton-wool spots
• Retinal hemorrhages
• Macular edema
• Capillary nonperfusion
• Neovascularization

Concurrent retinal disease may contribute to visual loss.

Diagnosis

RION is principally a:

Diagnosis of clinical context + characteristic imaging + exclusion of recurrent tumor and other causes

There is no single laboratory test that confirms it.

History

Obtain detailed information about:

• Original tumor
• Radiation field
• Total radiation dose
• Fraction size
• Radiation modality
• Date of treatment
• Re-irradiation
• Chemotherapy
• Prior visual function

Radiation treatment records are extremely useful if available.

MRI – Investigation of Choice

Obtain:

MRI of the brain and orbits with and without contrast

with:

• Thin orbital sections
• Fat-suppressed postcontrast imaging
• Dedicated evaluation of optic nerves and chiasm

MRI Findings

Characteristic findings may include:

• Focal or segmental enhancement of the affected optic nerve
• Chiasmal enhancement
• T2 hyperintensity
• Mild nerve enlargement in some cases

Enhancement may involve only a short segment and can be missed if imaging is not optimized.

Important MRI Principle

Enhancement of an irradiated optic nerve is:

Not specific for RION

because similar enhancement can occur with:

• Tumor infiltration
• Optic neuritis
• Sarcoidosis
• Infection
• Perineuritis

Therefore imaging must be interpreted in the clinical context.

Excluding Tumor Recurrence

One of the most important goals of imaging is to exclude:

• Recurrent tumor
• Progressive tumor
• New compressive lesion
• Radiation-induced secondary neoplasm

Serial comparison with previous MRI is particularly valuable.

OCT

Optical coherence tomography is useful for documenting structural injury.

Assess:

• Peripapillary RNFL
• Macular GCIPL/GCC

Early disease may show:

• RNFL thickening if disc edema is present

Later disease typically shows:

• RNFL thinning
• Ganglion cell loss

Ganglion Cell Analysis

Macular GCIPL/GCC may reveal:

Early retrograde axonal degeneration

and can be useful for:

• Baseline documentation
• Monitoring progression
• Correlating structural loss with visual fields

Visual Fields

Automated perimetry should be performed whenever visual function permits.

It helps:

• Localize the lesion
• Document severity
• Monitor progression

Fluorescein Angiography

FA is not routinely required for isolated RION but is useful when evaluating:

• Concurrent radiation retinopathy
• Macular ischemia
• Retinal vascular leakage

Laboratory Evaluation

Laboratory testing is directed by the differential diagnosis rather than RION itself.

Consider testing for:

• Inflammatory disease
• Infection
• Giant cell arteritis in appropriate older patients
• Nutritional/toxic causes

when the clinical picture is atypical.

Lumbar Puncture

CSF examination may be considered when there is concern for:

• Meningeal carcinomatosis
• Malignant infiltration
• Inflammatory optic neuropathy
• Infection

It is not routinely required for classic RION.

Differential Diagnosis

Important differentials include:

• Recurrent or progressive tumor
• Compressive optic neuropathy
• Tumor infiltration of optic nerve
• Meningeal carcinomatosis
• Optic neuritis
• Anterior ischemic optic neuropathy
• Posterior ischemic optic neuropathy
• Radiation retinopathy
• Sarcoidosis
• Optic perineuritis
• Toxic/nutritional optic neuropathy
• Paraneoplastic optic neuropathy
• Radiation-induced secondary tumor

RION vs Recurrent Tumor

RION

Usually:

• Delayed after radiotherapy
• Relatively abrupt visual decline
• Segmental optic pathway enhancement
• No progressively enlarging mass

Recurrent Tumor

More likely:

• Progressive mass on serial imaging
• Increasing compression
• Associated cranial neuropathies
• Progressive orbital or neurologic signs

The distinction may occasionally require:

• Serial MRI
• Multidisciplinary neuroradiology review

RION vs Optic Neuritis

RION

• History of radiation
• Usually older or tumor-treated population
• Often profound vision loss
• Usually little or no pain
• Poor recovery

Typical Optic Neuritis

• Often younger patient
• Pain with eye movement common
• Demyelinating context
• Greater likelihood of spontaneous recovery

RION vs NAION

NAION typically has:

• Acute painless visual loss
• Disc edema at onset
• Altitudinal field defect
• Crowded fellow optic disc

RION may have:

• Normal disc at onset
• Retrobulbar segmental enhancement
• Prior radiation exposure

Treatment

There is currently:

No treatment of consistently proven efficacy for established RION.

This remains one of the most important clinical realities.

Corticosteroids

Systemic corticosteroids have been used empirically.

However:

There is no convincing evidence that corticosteroids reliably restore vision in RION.

They may be considered if:

• Inflammatory optic neuropathy remains in the differential

but should not be presented as established treatment for radiation injury.

Hyperbaric Oxygen Therapy

Hyperbaric oxygen has been used because of the hypothesis that increasing tissue oxygenation may improve ischemic injury.

Potential benefit appears most plausible when initiated:

Very early after visual loss

before irreversible optic nerve infarction develops.

However:

• Evidence is limited
• Results are inconsistent
• Controlled data are lacking

Therefore HBO remains:

Unproven and controversial

rather than standard therapy.

Anti-VEGF Therapy

Intravitreal or systemic anti-VEGF therapy has been reported in small series and case reports.

A theoretical rationale is reduction of:

• Vascular permeability
• Radiation-associated microvascular leakage

However:

Anti-VEGF is not established therapy for isolated RION.

It is much better established for:

• Radiation maculopathy
• Radiation retinopathy

Bevacizumab

Some small reports have described visual stabilization or improvement with bevacizumab, particularly in anterior radiation optic neuropathy with associated disc edema.

Evidence remains insufficient for routine recommendation.

Anticoagulation

Anticoagulants and antiplatelet drugs have been tried based on the vascular hypothesis.

There is:

No established evidence of benefit

for routine use solely for RION.

Pentoxifylline and Vitamin E

These agents have been studied for other radiation-induced tissue injuries.

Their role in RION remains:

Unproven.

Surgical Treatment

There is no surgical treatment for the radiation injury itself.

Surgery may be required only when imaging reveals another treatable cause such as:

• Recurrent compressive tumor
• Radiation-induced mass

Prevention

Because treatment is unreliable:

Prevention is the most important strategy.

Radiation Planning

Preventive measures include:

• Respecting optic nerve/chiasm dose constraints
• Minimizing fraction size
• Using conformal planning
• IMRT
• Proton therapy in selected cases
• Fractionated stereotactic techniques when close to optic pathways
• Avoiding unnecessary re-irradiation

Multidisciplinary Planning

Treatment planning near the optic apparatus should involve:

• Radiation oncology
• Neurosurgery
• Neuro-ophthalmology when appropriate

The goal is to balance:

Tumor control against risk of irreversible visual pathway injury.

Follow-Up After Radiation Near the Optic Pathways

Patients should be educated to report:

• New blurred vision
• Color desaturation
• Visual field loss
• Sudden monocular or binocular visual change

promptly.

Clinical surveillance may include:

• Visual acuity
• Color vision
• Pupillary testing
• Visual fields
• OCT

when the optic apparatus received significant radiation exposure.

Prognosis

Visual prognosis after established RION is generally:

Poor

because the injury represents structural ischemic and radiotoxic damage.

Many affected eyes are left with:

• Severe visual impairment
• Permanent field loss
• Optic atrophy

Bilateral Disease

If both optic nerves or the chiasm are affected, patients may develop:

• Severe bilateral visual impairment
• Legal blindness
• Functional dependence

Early low-vision rehabilitation is important.

Low-Vision Rehabilitation

Patients with permanent bilateral impairment should be referred for:

• Low-vision evaluation
• Magnification
• Electronic visual aids
• Orientation and mobility training
• Occupational rehabilitation
• Blind-services support when appropriate

Complications

The principal complications are:

• Permanent optic atrophy
• Severe visual field loss
• Profound unilateral visual loss
• Bilateral blindness
• Associated radiation retinopathy
• Loss of independence in severe bilateral cases

Ophthalmology Pearls

• Radiation-induced optic neuropathy is a delayed, usually severe optic neuropathy occurring after radiation exposure to the optic nerve, chiasm, or nearby structures.
• Typical presentation is painless, sudden or rapidly progressive visual loss months to years after radiation therapy.
• Risk rises with increasing total dose, fraction size, re-irradiation, and proximity of the optic apparatus to the radiation field.
• Conventional fractionated doses above approximately 50–55 Gy to the optic nerve/chiasm substantially increase risk, although no dose is absolutely risk-free.
• The mechanism involves both radiation-induced microvascular ischemia and direct neural/glial injury.
• MRI with thin-section, fat-suppressed postcontrast orbital imaging is the key investigation.
• RION commonly produces segmental enhancement of the affected optic nerve or chiasm, but enhancement is not specific.
• The most important competing diagnosis is recurrent or progressive tumor, which must be excluded before attributing visual loss to radiation.
• The optic disc may be normal initially; optic atrophy develops later.
• OCT typically demonstrates progressive RNFL and GCIPL/GCC loss after the acute injury.
• There is no treatment with consistently proven visual benefit once RION is established.
• Hyperbaric oxygen has occasionally been attempted very early but remains unproven and controversial.
• Corticosteroids, anticoagulation, anti-VEGF, pentoxifylline, and vitamin E have been reported, but none is established standard therapy for isolated RION.
• Anti-VEGF has a much clearer role in radiation retinopathy/maculopathy than in optic neuropathy.
• Because treatment is unreliable, the key strategy is prevention through careful radiation dose planning and optic pathway constraints.
• Severe bilateral visual loss warrants early low-vision rehabilitation and blind-services support.

Clinical Importance New visual loss in a patient with previous radiation near the optic pathways should prompt urgent evaluation for:  Radiation-induced optic neuropathy Recurrent/compressive tumor Tumor infiltration Optic neuritis Ischemic optic neuropathy Meningeal carcinomatosis Radiation retinopathy  The diagnosis should not be assumed solely because of a history of radiotherapy.

Epidemiology RION is uncommon with modern radiation planning but remains a serious delayed complication. Risk is strongly related to:  Total radiation dose Dose per fraction Volume of optic nerve/chiasm irradiated Radiation technique Patient-specific vascular susceptibility

Latency RION most often develops: Several months to several years after treatment A common interval is approximately: 1–3 years but cases may occur earlier or substantially later. A very long latency does not completely exclude RION.

Laterality Disease may be:  Unilateral Sequentially bilateral Bilateral simultaneously  If the chiasm is involved, both eyes may be affected through:  Chiasmal field loss Bilateral optic nerve dysfunction

Risk Factors Important risk factors include:  High radiation dose to the optic apparatus Large dose per fraction Stereotactic/high-dose focal treatment near optic nerve or chiasm Re-irradiation Concurrent or prior chemotherapy Diabetes mellitus Hypertension Preexisting optic nerve compression Other vascular risk factors

Radiation Dose and Risk For conventional fractionated radiotherapy, the risk of RION rises substantially when the optic nerve or chiasm receives doses above approximately: 50–55 Gy particularly when:  Fraction size exceeds approximately 1.8–2 Gy Large segments of the optic pathway are irradiated  Modern radiation planning generally attempts to keep maximum optic nerve/chiasm dose below established organ-at-risk constraints whenever tumor control allows.

Stereotactic Radiosurgery The optic nerve and chiasm are particularly sensitive to: High single-fraction doses Therefore single-fraction radiosurgery immediately adjacent to a functioning optic apparatus requires strict dose limitation. Fractionated stereotactic radiotherapy may be preferred when a lesion lies very close to:  Optic nerve Chiasm  because fractionation reduces the risk of delayed radiation injury.

Pathophysiology RION is believed to result from a combination of:  Radiation-induced vascular injury Endothelial damage Capillary occlusion Ischemia Demyelination Direct glial and axonal injury

Vascular Injury Radiation damages small blood vessels through:  Endothelial proliferation Fibrinoid necrosis Obliterative endarteritis Capillary closure  The result is: Chronic ischemia of the optic nerve

Parenchymal Injury Radiation may also directly damage:  Oligodendrocytes Astrocytes Myelin Axons  leading to:  Demyelination Necrosis Axonal loss  The final pathology is therefore both: Vascular and neural.

Clinical Presentation The classic symptom is: Painless visual loss which may be:  Sudden Subacute Rapidly progressive over days to weeks  Vision loss is often severe.

Visual Acuity Visual acuity may decline to:  20/200 or worse Counting fingers Hand motions No light perception in severe cases  Visual prognosis is generally poor once substantial injury is established.

Color Vision Patients commonly have: Marked dyschromatopsia consistent with optic nerve dysfunction.

Pupillary Findings If involvement is unilateral or asymmetric: Relative afferent pupillary defect (RAPD) is expected. Bilateral symmetric disease may produce no obvious RAPD.

Visual Fields Field defects depend on the location of injury. Optic Nerve Possible defects include:  Central scotoma Cecocentral scotoma Arcuate defect Altitudinal defect Diffuse depression  Optic Chiasm May produce:  Bitemporal hemianopic defects  Optic Tract May produce:  Contralateral homonymous visual field loss

Optic Disc Appearance At onset, the optic disc may appear:  Normal Mildly swollen Pale if there was prior compressive damage  Anterior optic nerve involvement may produce: Disc edema but many cases are retrobulbar and initially have a normal-appearing disc.

Optic Atrophy Over subsequent weeks: Optic disc pallor develops because of irreversible axonal loss. This may be accompanied by:  RNFL thinning Ganglion cell loss

Radiation Retinopathy RION may coexist with: Radiation retinopathy especially when the globe was within the radiation field. Look for:  Microaneurysms Cotton-wool spots Retinal hemorrhages Macular edema Capillary nonperfusion Neovascularization  Concurrent retinal disease may contribute to visual loss.

Diagnosis RION is principally a: Diagnosis of clinical context + characteristic imaging + exclusion of recurrent tumor and other causes There is no single laboratory test that confirms it.

History Obtain detailed information about:  Original tumor Radiation field Total radiation dose Fraction size Radiation modality Date of treatment Re-irradiation Chemotherapy Prior visual function  Radiation treatment records are extremely useful if available.

MRI – Investigation of Choice Obtain: MRI of the brain and orbits with and without contrast with:  Thin orbital sections Fat-suppressed postcontrast imaging Dedicated evaluation of optic nerves and chiasm

MRI Findings Characteristic findings may include:  Focal or segmental enhancement of the affected optic nerve Chiasmal enhancement T2 hyperintensity Mild nerve enlargement in some cases  Enhancement may involve only a short segment and can be missed if imaging is not optimized.

Important MRI Principle Enhancement of an irradiated optic nerve is: Not specific for RION because similar enhancement can occur with:  Tumor infiltration Optic neuritis Sarcoidosis Infection Perineuritis  Therefore imaging must be interpreted in the clinical context.

Excluding Tumor Recurrence One of the most important goals of imaging is to exclude:  Recurrent tumor Progressive tumor New compressive lesion Radiation-induced secondary neoplasm  Serial comparison with previous MRI is particularly valuable.

OCT Optical coherence tomography is useful for documenting structural injury. Assess:  Peripapillary RNFL Macular GCIPL/GCC  Early disease may show:  RNFL thickening if disc edema is present  Later disease typically shows:  RNFL thinning Ganglion cell loss

Ganglion Cell Analysis Macular GCIPL/GCC may reveal: Early retrograde axonal degeneration and can be useful for:  Baseline documentation Monitoring progression Correlating structural loss with visual fields

Visual Fields Automated perimetry should be performed whenever visual function permits. It helps:  Localize the lesion Document severity Monitor progression

Fluorescein Angiography FA is not routinely required for isolated RION but is useful when evaluating:  Concurrent radiation retinopathy Macular ischemia Retinal vascular leakage

Laboratory Evaluation Laboratory testing is directed by the differential diagnosis rather than RION itself. Consider testing for:  Inflammatory disease Infection Giant cell arteritis in appropriate older patients Nutritional/toxic causes  when the clinical picture is atypical.

Lumbar Puncture CSF examination may be considered when there is concern for:  Meningeal carcinomatosis Malignant infiltration Inflammatory optic neuropathy Infection  It is not routinely required for classic RION.

Differential Diagnosis Important differentials include:  Recurrent or progressive tumor Compressive optic neuropathy Tumor infiltration of optic nerve Meningeal carcinomatosis Optic neuritis Anterior ischemic optic neuropathy Posterior ischemic optic neuropathy Radiation retinopathy Sarcoidosis Optic perineuritis Toxic/nutritional optic neuropathy Paraneoplastic optic neuropathy Radiation-induced secondary tumor

RION vs Recurrent Tumor RION Usually:  Delayed after radiotherapy Relatively abrupt visual decline Segmental optic pathway enhancement No progressively enlarging mass  Recurrent Tumor More likely:  Progressive mass on serial imaging Increasing compression Associated cranial neuropathies Progressive orbital or neurologic signs  The distinction may occasionally require:  Serial MRI Multidisciplinary neuroradiology review

RION vs Optic Neuritis RION  History of radiation Usually older or tumor-treated population Often profound vision loss Usually little or no pain Poor recovery  Typical Optic Neuritis  Often younger patient Pain with eye movement common Demyelinating context Greater likelihood of spontaneous recovery

RION vs NAION NAION typically has:  Acute painless visual loss Disc edema at onset Altitudinal field defect Crowded fellow optic disc  RION may have:  Normal disc at onset Retrobulbar segmental enhancement Prior radiation exposure

Treatment There is currently: No treatment of consistently proven efficacy for established RION. This remains one of the most important clinical realities.

Corticosteroids Systemic corticosteroids have been used empirically. However: There is no convincing evidence that corticosteroids reliably restore vision in RION. They may be considered if:  Inflammatory optic neuropathy remains in the differential  but should not be presented as established treatment for radiation injury.

Hyperbaric Oxygen Therapy Hyperbaric oxygen has been used because of the hypothesis that increasing tissue oxygenation may improve ischemic injury. Potential benefit appears most plausible when initiated: Very early after visual loss before irreversible optic nerve infarction develops. However:  Evidence is limited Results are inconsistent Controlled data are lacking  Therefore HBO remains: Unproven and controversial rather than standard therapy.

Anti-VEGF Therapy Intravitreal or systemic anti-VEGF therapy has been reported in small series and case reports. A theoretical rationale is reduction of:  Vascular permeability Radiation-associated microvascular leakage  However: Anti-VEGF is not established therapy for isolated RION. It is much better established for:  Radiation maculopathy Radiation retinopathy

Bevacizumab Some small reports have described visual stabilization or improvement with bevacizumab, particularly in anterior radiation optic neuropathy with associated disc edema. Evidence remains insufficient for routine recommendation.

Anticoagulation Anticoagulants and antiplatelet drugs have been tried based on the vascular hypothesis. There is: No established evidence of benefit for routine use solely for RION.

Pentoxifylline and Vitamin E These agents have been studied for other radiation-induced tissue injuries. Their role in RION remains: Unproven.

Surgical Treatment There is no surgical treatment for the radiation injury itself. Surgery may be required only when imaging reveals another treatable cause such as:  Recurrent compressive tumor Radiation-induced mass

Prevention Because treatment is unreliable: Prevention is the most important strategy.

Radiation Planning Preventive measures include:  Respecting optic nerve/chiasm dose constraints Minimizing fraction size Using conformal planning IMRT Proton therapy in selected cases Fractionated stereotactic techniques when close to optic pathways Avoiding unnecessary re-irradiation

Multidisciplinary Planning Treatment planning near the optic apparatus should involve:  Radiation oncology Neurosurgery Neuro-ophthalmology when appropriate  The goal is to balance: Tumor control against risk of irreversible visual pathway injury.

Follow-Up After Radiation Near the Optic Pathways Patients should be educated to report:  New blurred vision Color desaturation Visual field loss Sudden monocular or binocular visual change  promptly. Clinical surveillance may include:  Visual acuity Color vision Pupillary testing Visual fields OCT  when the optic apparatus received significant radiation exposure.

Prognosis Visual prognosis after established RION is generally: Poor because the injury represents structural ischemic and radiotoxic damage. Many affected eyes are left with:  Severe visual impairment Permanent field loss Optic atrophy

Bilateral Disease If both optic nerves or the chiasm are affected, patients may develop:  Severe bilateral visual impairment Legal blindness Functional dependence  Early low-vision rehabilitation is important.

Low-Vision Rehabilitation Patients with permanent bilateral impairment should be referred for:  Low-vision evaluation Magnification Electronic visual aids Orientation and mobility training Occupational rehabilitation Blind-services support when appropriate

Complications The principal complications are:  Permanent optic atrophy Severe visual field loss Profound unilateral visual loss Bilateral blindness Associated radiation retinopathy Loss of independence in severe bilateral cases

Ophthalmology Pearls  Radiation-induced optic neuropathy is a delayed, usually severe optic neuropathy occurring after radiation exposure to the optic nerve, chiasm, or nearby structures. Typical presentation is painless, sudden or rapidly progressive visual loss months to years after radiation therapy. Risk rises with increasing total dose, fraction size, re-irradiation, and proximity of the optic apparatus to the radiation field. Conventional fractionated doses above approximately 50–55 Gy to the optic nerve/chiasm substantially increase risk, although no dose is absolutely risk-free. The mechanism involves both radiation-induced microvascular ischemia and direct neural/glial injury. MRI with thin-section, fat-suppressed postcontrast orbital imaging is the key investigation. RION commonly produces segmental enhancement of the affected optic nerve or chiasm, but enhancement is not specific. The most important competing diagnosis is recurrent or progressive tumor, which must be excluded before attributing visual loss to radiation. The optic disc may be normal initially; optic atrophy develops later. OCT typically demonstrates progressive RNFL and GCIPL/GCC loss after the acute injury. There is no treatment with consistently proven visual benefit once RION is established. Hyperbaric oxygen has occasionally been attempted very early but remains unproven and controversial. Corticosteroids, anticoagulation, anti-VEGF, pentoxifylline, and vitamin E have been reported, but none is established standard therapy for isolated RION. Anti-VEGF has a much clearer role in radiation retinopathy/maculopathy than in optic neuropathy. Because treatment is unreliable, the key strategy is prevention through careful radiation dose planning and optic pathway constraints. Severe bilateral visual loss warrants early low-vision rehabilitation and blind-services support.